The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen.
Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.
The University of Aberdeen has led the way on research into the little-understood condition which was only recognised in the late 1990s. Takotsubo cardiomyopathy affects around 5,000 people in the UK each year, with at least 7% of all of heart attacks diagnosed as broken heart syndrome.
The new trial will recruit 90 people from across Scotland within three weeks of them experiencing an episode. Meanwhile, participants will either take part in personalised exercise conditioning, a programme of cognitive behavioural therapy or be part of a control group. All participants will receive detailed heart investigations at baseline and again at three months. The study will span three years.
Currently there is no evidence base for an effective therapy that helps alleviate symptoms or to help people live longer. Women are far more likely to experience the condition than men.
Dr David Gamble from the University of Aberdeen, explained: “Takotsubo cardiomyopathy, or broken heart syndrome, remains a comparatively poorly understood condition. It is vital that we develop a high-quality evidence base to guide clinicians in the management of this condition.
“In many clinical intervention trials, we are attempting to make incremental improvements to existing treatments, but as broken heart syndrome is at such an early stage there is no established treatment to use as a base.”
Professor Dana Dawson of the University of Aberdeen, said: “We already know that cardiovascular disease affects men and women in different ways, so there is no reason why a one-size-fits-all treatment should work for broken heart syndrome.
“After so long spent researching this condition, it is great to be taking this huge step towards developing a standardised treatment for it and we look forward to seeing the results in due course.”
Professor James Leiper, associate medical director at the British Heart Foundation, added: “Takotsubo syndrome is a sudden and potentially catastrophic heart condition which has only been recognised in recent years. As such, these trials to find the first ever treatment for the condition are a huge step forward and will play a significant role in increasing our understanding of this neglected area of cardiology.”
by John Pinching
Source: pharmatimes.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
